Conference abstract · 12 Mar 2018
Conference abstractPublished 29 Mar 2018
Drug development: Ethics versus efficacy
Saveetha Medical College, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: To analyze the post-marketing status of molecules approved through the expedited review process in the last quintile. Methods: The observational study was carried out between January 2016 and June 2016. The details of the time taken to approve drugs were collected from the official website on the United States Food and Drug Administration (FDA). The average time taken to review drugs and take a decision following the review was ascertained from the FDAâÂ?Â?s annual release of novel drugs from 2011 to 2015. Information on adverse drug reaction noted after approval was gathered from FDA Drug Safety Communication and FDA Adverse Event Reporting System (FAERS). Results: In the last five years, 166 products were approved by expedited review. Of these 45 (27.1%) did not meet the stringent criteria framed for expedited review. Reports of serious adverse event alerts were submitted for 79 (47.5%) of the 166 molecules. 14 (8.4%) drugs were associated with inducing severe autoimmune disorders. It can be observed that a lower average time of review is positively correlated with a greater number of adverse events (p<0.05) and 37 (45.7%) of the molecules failed to be of any treatment scenario. Conclusion: Drug approval by accelerated review should be stringent. Beneficence and non-maleficence are applicable to the global population and should apply equally to subjects involved in trials. Approving drugs on the basis of trivial evidence is non-scientific and absolutely unethical, since it can lead to clinical failure and produce serious adverse events.
Subjects
ToxicologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 31 Jan 2024
Pharmacological Safety in Drug Development: Ensuring Efficacy with Minimal
Perspective · 31 Mar 2023
Balancing Efficacy and Safety: The Importance of Ongoing Research and Monitoring in Drug Development and Targeting
Commentary · 31 Mar 2023
Balancing Safety and Efficacy: Challenges in Developing Chemical Drugs.
Short communication · 2010
The Post-Transcriptional Regulator EIF2S3 and Gender Differences in the Dog: Implications for Drug Development, Drug Efficacy and Safety Profiles
More from this journal
The newest in Toxicology: Open Access.
Editorial · 1 Dec 2025
Aflatoxin Contamination: Health Risks and Solutions
Editorial · 1 Dec 2025
Heavy Metals: Toxicity, Risks, and Prevention
Editorial · 1 Dec 2025
Occupational Health and Safety: Key Research Areas
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalToxicology: Open Access
- SubjectToxicology
- BylineArticles whose byline prints “Kumaresh Pandian”
- BylineArticles whose byline prints “Krishnan V”
